New Chinese Biosensing Platform Enables Comprehensive T-Cell Immune Monitoring Using Single Drop of Fingertip Blood

The TOI-IGRA platform uses a single drop of fingertip blood to provide a full picture of T-cell and antibody immunity, revolutionizing infectious disease checks.

By: AXL Media

Published: Mar 19, 2026, 4:34 AM EDT

Source: Information for this report was sourced from Shenzhen Institute of Advanced Technology

Revolutionizing Cellular Immune Surveillance

A significant gap in public health monitoring has been the difficulty of assessing T-cell responses outside of high-end laboratory settings. While traditional antibody tests provide a snapshot of humoral immunity, T-cells offer a more complete picture of long-term protection against intracellular threats. The newly developed Tip Optofluidic Immunoassay Interferon-Gamma Release Assay (TOI-IGRA) platform addresses this by moving away from the need for large venous blood draws. Led by Professor Tan Xiaotian, the research team from the Chinese Academy of Sciences has created a system that brings sophisticated immunological analysis to community clinics and resource-limited environments.

The Science of Micro-Volume Stimulation

The technical breakthrough of the TOI-IGRA platform lies in its specialized micro-volume stimulation protocol, which ensures that tiny amounts of blood remain viable for testing. By optimizing anticoagulation and utilizing a specific 0.9% NaCl environment for dilution, the researchers proved that 15 to 25 microliters of fingertip blood maintains an immune cell composition nearly identical to traditional venous samples. This precision allows the TOI biosensing system to accurately quantify how a patient’s T-cells respond to specific pathogens without requiring the milliliters of blood typically demanded by standard Interferon-Gamma Release Assays (IGRA).

A Dual-Modal Approach to Immunity

One of the platform's most innovative features is its dual-modal testing capability, which evaluates both branches of the immune system simultaneously. From a single micro-sample, the device can conduct a functional analysis of T-cells while also performing a quantitative antibody assay. This holistic view provides healthcare providers with data on both cellular and humoral protection at once, offering a more nuanced understanding of an individual's defense against infection. According to the study published in Analytical Chemistry, this combined data set is far more predictive of real-world immunity than antibody counts alone.